Jorge Plutzky
#150,547
Most Influential Person Now
Jorge Plutzky's AcademicInfluence.com Rankings
Jorge Plutzkymedical Degrees
Medical
#2896
World Rank
#3340
Historical Rank
Cardiology
#284
World Rank
#290
Historical Rank

Jorge Plutzkyphilosophy Degrees
Philosophy
#8299
World Rank
#11652
Historical Rank
Logic
#5334
World Rank
#6725
Historical Rank

Download Badge
Medical Philosophy
Jorge Plutzky's Degrees
- Doctorate Medicine Harvard University
Why Is Jorge Plutzky Influential?
(Suggest an Edit or Addition)Jorge Plutzky's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. (1998) (1937)
- International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors (2006) (946)
- Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. (1998) (630)
- Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus (2007) (587)
- PPARα Activators Inhibit Cytokine-Induced Vascular Cell Adhesion Molecule-1 Expression in Human Endothelial Cells (1999) (568)
- Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies (2008) (525)
- Macrophages in Human Atheroma Contain PPARγ: Differentiation-Dependent Peroxisomal Proliferator-Activated Receptor γ (PPARγ) Expression and Reduction of MMP-9 Activity through PPARγ Activation in Mononuclear Phagocytes in Vitro (1998) (516)
- NF-κB directs dynamic super enhancer formation in inflammation and atherogenesis. (2014) (480)
- The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. (2008) (473)
- The pathologic continuum of diabetic vascular disease. (2009) (420)
- Discontinuation of Statins in Routine Care Settings (2013) (392)
- The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). (2006) (387)
- PPAR Activators as Antiinflammatory Mediators in Human T Lymphocytes: Implications for Atherosclerosis and Transplantation-Associated Arteriosclerosis (2002) (370)
- PPARγ Activation in Human Endothelial Cells Increases Plasminogen Activator Inhibitor Type-1 Expression PPARγ as a Potential Mediator in Vascular Disease (1999) (361)
- Identification of a human src homology 2-containing protein-tyrosine-phosphatase: a putative homolog of Drosophila corkscrew. (1992) (342)
- BET Bromodomains Mediate Transcriptional Pause Release in Heart Failure (2013) (333)
- Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. (2007) (325)
- Retinaldehyde represses adipogenesis and diet-induced obesity (2007) (303)
- Inflammatory pathways in atherosclerosis and acute coronary syndromes. (2001) (288)
- Isolation of a src homology 2-containing tyrosine phosphatase. (1992) (282)
- Peroxisome Proliferator-Activated Receptor-γ Activators Inhibit IFN-γ-Induced Expression of the T Cell-Active CXC Chemokines IP-10, Mig, and I-TAC in Human Endothelial Cells1 (2000) (279)
- The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients (2008) (261)
- Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: Evidence for an antiinflammatory role for lipoprotein lipase (2003) (253)
- Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. (1998) (245)
- Retinoid metabolism and nuclear receptor responses: New insights into coordinated regulation of the PPAR–RXR complex (2008) (210)
- PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. (1999) (196)
- Diabetes and Cardiovascular Disease in Older Adults: Current Status and Future Directions (2014) (192)
- Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. (2015) (190)
- Retinaldehyde dehydrogenase 1 regulates a thermogenic program in white adipose tissue (2012) (189)
- The transcription factor cyclic AMP–responsive element–binding protein H regulates triglyceride metabolism (2011) (189)
- PPARα in atherosclerosis and inflammation (2007) (171)
- Evolution and organization of the human protein C gene. (1986) (170)
- Brown Fat and Browning for the Treatment of Obesity and Related Metabolic Disorders (2016) (166)
- PPAR&agr; Activators Inhibit Tissue Factor Expression and Activity in Human Monocytes (2001) (164)
- Oxidized omega-3 fatty acids in fish oil inhibit leukocyte-endothelial interactions through activation of PPAR alpha. (2002) (159)
- Residual macrovascular risk in 2013: what have we learned? (2014) (157)
- The vascular biology of atherosclerosis. (2003) (156)
- Discontinuation of Statin in Routine Care Settings: A Cohort Study (2013) (154)
- PPARs and their metabolic modulation: new mechanisms for transcriptional regulation? (2007) (149)
- Diabetic macrovascular disease: the glucose paradox? (2002) (144)
- PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. (1999) (144)
- PPARgamma in the endothelium regulates metabolic responses to high-fat diet in mice. (2008) (142)
- Reciprocal and Coordinate Regulation of Serum Amyloid A Versus Apolipoprotein A-I and Paraoxonase-1 by Inflammation in Murine Hepatocytes (2006) (141)
- The structure and evolution of a 461 amino acid human protein C precursor and its messenger RNA, based upon the DNA sequence of cloned human liver cDNAs. (1985) (137)
- Deletion of the α-Arrestin Protein Txnip in Mice Promotes Adiposity and Adipogenesis While Preserving Insulin Sensitivity (2010) (136)
- Asymmetric cleavage of beta-carotene yields a transcriptional repressor of retinoid X receptor and peroxisome proliferator-activated receptor responses. (2007) (130)
- Cardiovascular Risk and Statin Eligibility of Young Adults After an MI: Partners YOUNG-MI Registry. (2017) (129)
- Endothelial cell-fatty acid binding protein 4 promotes angiogenesis: role of stem cell factor/c-kit pathway (2012) (123)
- Inflammation in Diabetes Mellitus: Role of Peroxisome Proliferator-Activated Receptor–α and Peroxisome Proliferator-Activated Receptor–γ Agonists (2007) (117)
- The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part II: Clinical trial evidence (acute coronary syndromes through renal disease) and future directions. (2006) (116)
- A diurnal serum lipid integrates hepatic lipogenesis and peripheral fatty acid utilization (2013) (115)
- The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice. (2008) (113)
- Alanine for Proline Substitution in the Peroxisome Proliferator–Activated Receptor Gamma-2 (PPARG2) Gene and the Risk of Incident Myocardial Infarction (2003) (113)
- The PPAR-RXR Transcriptional Complex in the Vasculature: Energy in the Balance (2011) (107)
- Atherosclerotic plaque rupture: emerging insights and opportunities. (1999) (100)
- Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. (2000) (99)
- PPARs as Therapeutic Targets: Reverse Cardiology? (2003) (96)
- Leukotriene E4 Activates Peroxisome Proliferator-activated Receptor γ and Induces Prostaglandin D2 Generation by Human Mast Cells* (2008) (95)
- Osteopontin deficiency protects against obesity-induced hepatic steatosis and attenuates glucose production in mice (2011) (93)
- Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets. (2002) (91)
- Epigenetic Changes in Diabetes and Cardiovascular Risk. (2016) (90)
- PPARalpha in atherosclerosis and inflammation. (2007) (90)
- Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. (2020) (90)
- Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: Emerging insights for evolving paradigms (2000) (87)
- Retinaldehyde dehydrogenase 1 coordinates hepatic gluconeogenesis and lipid metabolism. (2012) (86)
- High-Density Lipoprotein Hydrolysis by Endothelial Lipase Activates PPAR&agr;: A Candidate Mechanism for High-Density Lipoprotein–Mediated Repression of Leukocyte Adhesion (2006) (85)
- The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential (2019) (84)
- A Review of Metabolic and Cardiovascular Effects of Oral Antidiabetic Agents: Beyond Glucose-Level Lowering (1999) (83)
- Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials. (2014) (79)
- The potential role of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis. (2003) (78)
- VLDL hydrolysis by LPL activates PPAR-α through generation of unbound fatty acids (2010) (67)
- Dual Roles for Lipolysis and Oxidation in Peroxisome Proliferation-Activator Receptor Responses to Electronegative Low Density Lipoprotein* (2003) (67)
- The biology of atherosclerosis: general paradigms and distinct pathogenic mechanisms among HIV-infected patients. (2012) (66)
- Peroxisome Proliferator-Activated Receptors (PPARs) and Their Role in the Vessel Wall: Possible Mediators of Cardiovascular Risk? (2001) (63)
- Emerging concepts in metabolic abnormalities associated with coronary artery disease (2000) (61)
- Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists. (2007) (61)
- Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of Bempedoic acid on cardiovascular events in patients with statin intolerance. (2020) (61)
- Continued Statin Prescriptions After Adverse Reactions and Patient Outcomes (2017) (60)
- Familial Hypercholesterolemia Among Young Adults With Myocardial Infarction. (2019) (60)
- Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects. (2012) (59)
- Retinoid Metabolism and Diabetes Mellitus (2012) (59)
- Peroxisome proliferator-activated receptors in endothelial cell biology (2001) (58)
- BET Epigenetic Reader Proteins in Cardiovascular Transcriptional Programs. (2020) (57)
- Pioglitazone Suppresses Inflammation In Vivo in Murine Carotid Atherosclerosis: Novel Detection by Dual-Target Fluorescence Molecular Imaging (2010) (56)
- Insights into the Molecular Mechanisms of the Anti-Atherogenic Actions of Flavonoids in Normal and Obese Mice (2011) (54)
- BET bromodomain proteins regulate enhancer function during adipogenesis (2018) (54)
- Retinoid metabolism and its effects on the vasculature. (2012) (50)
- Chromosomal localization of an SH2-containing tyrosine phosphatase (PTPN6). (1992) (47)
- Super enhancers at the miR-146a and miR-155 genes contribute to self-regulation of inflammation. (2016) (46)
- Macrovascular effects and safety issues of therapies for type 2 diabetes. (2011) (43)
- Drivers of the Sex Disparity in Statin Therapy in Patients with Coronary Artery Disease: A Cohort Study (2016) (43)
- Inflammation in Atherosclerosis and Diabetes Mellitus (2004) (41)
- Endothelial Lipase Is a Critical Determinant of High-Density Lipoprotein–Stimulated Sphingosine 1-Phosphate–Dependent Signaling in Vascular Endothelium (2013) (41)
- Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation. (2012) (40)
- Association of monocyte tumor necrosis factor α expression and serum inflammatory biomarkers with walking impairment in peripheral artery disease. (2015) (38)
- Enhanced fatty acid flux triggered by adiponectin overexpression. (2012) (37)
- Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable. (2018) (37)
- Remote Optimization of Guideline-Directed Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction. (2020) (35)
- Confronting the type 2 diabetes epidemic: the emerging role of incretin-based therapies. (2010) (34)
- Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review. (2020) (34)
- Structured vs. unstructured: factors affecting adverse drug reaction documentation in an EMR repository. (2011) (33)
- Peroxisome proliferator-activated receptors as therapeutic targets in inflammation. (2003) (31)
- Differential role of an NF-κB transcriptional response element in endothelial versus intimal cell VCAM-1 expression. (2015) (30)
- Insulin resistance, diabetes, and atherosclerosis: Thiazolidinediones as therapeutic interventions (2002) (29)
- Statins for stroke: the second story? (2001) (29)
- Medicine. PPARs as therapeutic targets: reverse cardiology? (2003) (27)
- Deficiency of Retinaldehyde Dehydrogenase 1 Induces BMP2 and Increases Bone Mass In Vivo (2013) (26)
- Digital Care Transformation: Interim Report From the First 5000 Patients Enrolled in a Remote Algorithm-Based Cardiovascular Risk Management Program to Improve Lipid and Hypertension Control. (2020) (25)
- Lipolytic PPAR activation: new insights into the intersection of triglycerides and inflammation? (2004) (25)
- Oxidative stress and peroxisome proliferator-activated receptors: reversing the curse? (2004) (25)
- Reductions in lipids and CV risk markers in patients with type 2 diabetes treated with liraglutide: a meta-analysis. (2009) (25)
- The incretin axis in cardiovascular disease. (2011) (24)
- Diabetes Is Associated With Worse Long-term Outcomes in Young Adults After Myocardial Infarction: The Partners YOUNG-MI Registry (2019) (24)
- VLDL Hydrolysis by Hepatic Lipase Regulates PPARδ Transcriptional Responses (2011) (24)
- Peroxisome proliferator-activated receptors (2002) (24)
- PPARa Activators Inhibit Cytokine-Induced Vascular Cell Adhesion Molecule-1 Expression in Human Endothelial Cells (1999) (22)
- Effect of a peroxisome proliferator-activated receptor-gamma agonist on myocardial blood flow in type 2 diabetes. (2005) (22)
- Fifty shades of brown: perivascular fat, thermogenesis, and atherosclerosis. (2012) (20)
- Association of Socioeconomic Disadvantage With Long-term Mortality After Myocardial Infarction: The Mass General Brigham YOUNG-MI Registry. (2021) (19)
- Discontinuation of Statins in Routine Care Settings (2013) (19)
- Liver X receptor activation and high-density lipoprotein biology: a reversal of fortune? (2005) (17)
- Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials (2018) (17)
- NHLBI Integrated Guidelines on Cardiovascular Disease Risk Reduction: can we clarify the controversy about cholesterol screening and treatment in childhood? (2012) (17)
- Peroxisome proliferator activated receptor gamma and its activation in the treatment of insulin resistance and atherosclerosis: issues and opportunities (2003) (17)
- Retinoids Repress Human Cardiovascular Cell Calcification With Evidence for Distinct Selective Retinoid Modulator Effects (2019) (16)
- A Roadmap on the Prevention of Cardiovascular Disease Among People Living With Diabetes. (2019) (16)
- Expansion and contraction: the mighty, mighty fatty acid (2009) (14)
- Secondary Prevention of Myocardial Infarction (1999) (14)
- Extensive metabolic disorders are present in APC min tumorigenesis mice (2016) (14)
- Distribution and Performance of Cardiovascular Risk Scores in a Mixed Population of HIV-Infected and Community-Based HIV-Uninfected Individuals in Uganda (2018) (14)
- Effect of lipid-lowering therapy on vasomotion and endothelial function (1999) (13)
- Prediabetes mellitus and its links to atherosclerosis (2003) (13)
- Lipids in RA: Is Less Not Necessarily More? (2018) (13)
- DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases (2021) (13)
- The BD2 domain of BRD4 is a determinant in EndoMT and vein graft neointima formation (2019) (12)
- Endothelial cell-fatty acid binding protein 4 promotes angiogenesis: role of stem cell factor/c-kit pathway (2012) (12)
- Inhibition of BET bromodomain attenuates angiotensin II induced abdominal aortic aneurysm in ApoE-/- mice. (2016) (11)
- Management of low levels of high-density lipoprotein-cholesterol. (2013) (11)
- Liraglutide, a once-daily human GLP-1 analogue, reduces systolic blood pressure within 2 weeks in patients with type 2 diabetes (2009) (10)
- Intact vitamin A transport is critical for cold-mediated adipose tissue browning and thermogenesis (2020) (10)
- Statin eligibility and cardiovascular risk burden assessed by coronary artery calcium score: comparing the two guidelines in a large Korean cohort. (2015) (10)
- Risk factors for lack of statin therapy in patients with diabetes and coronary artery disease. (2016) (10)
- Cardiovascular disease, chronic kidney disease, and type 2 diabetes mellitus: proceeding with caution at a dangerous intersection. (2008) (10)
- Preventing type 2 diabetes and cardiovascular disease in metabolic syndrome: the role of PPARα (2007) (10)
- Assessing Cardiovascular Risk in People Living with HIV: Current Tools and Limitations (2021) (10)
- Bridging the Gap for Patients with Diabetes and Cardiovascular Disease Through Cardiometabolic Collaboration (2019) (9)
- Adipocyte arrestin domain-containing 3 protein (Arrdc3) regulates uncoupling protein 1 (Ucp1) expression in white adipose independently of canonical changes in β-adrenergic receptor signaling (2017) (9)
- Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. (2023) (9)
- Diabetes and the Cardiovascular System (2013) (9)
- Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Diabetes Mellitus and Chronic Kidney Disease: Turning the Page (2018) (8)
- BRD2 regulation of sigma-2 receptor upon cholesterol deprivation (2020) (8)
- Retinaldehyde dehydrogenase 1 deficiency inhibits PPARγ-mediated bone loss and marrow adiposity. (2014) (8)
- On being a physician. (1990) (8)
- Results of a Remotely Delivered Hypertension and Lipid Program in More Than 10 000 Patients Across a Diverse Health Care Network. (2022) (8)
- WEIGHT LOSS, BLOOD PRESSURE, PULSE AND CIRCADIAN PATTERNS WITH NALTREXONE SUSTAINED-RELEASE/BUPROPION SUSTAINED-RELEASE COMBINATION THERAPY FOR OBESITY (2011) (6)
- Adiponectin concentration data improve the estimation of atherosclerotic risk in normal and in overweight subjects (2018) (6)
- A cardiologist's perspective on cardiometabolic risk. (2007) (5)
- Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low-density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia not treated with statins (2021) (5)
- Peroxisome Proliferator-Activated Receptor-g Activators Inhibit IFN- g-Induced Expression of the T Cell-Active CXC Chemokines IP-10, Mig, and I-TAC in Human Endothelial Cells (2000) (5)
- Atherosclerotic cardiovascular disease risk and elevated lipoprotein(a) among young adults with myocardial infarction: The Partners YOUNG-MI Registry. (2020) (5)
- Divergence of Cardiovascular Biomarkers of Lipids and Subclinical Myocardial Injury Among Rheumatoid Arthritis Patients With Increased Inflammation (2020) (5)
- Leukotriene E 4 Activates Peroxisome Proliferator-activated Receptor and Induces Prostaglandin D 2 Generation by (2008) (5)
- Predictors of a successful statin reattempt after an adverse reaction. (2018) (5)
- Mellitus: A Scientific Statement From the American Heart Association and the Primary Prevention of Cardiovascular Diseases in People With Diabetes (2007) (5)
- The role of cardiologists in the management of patients with diabetes is evolving owing to the close relationship between diabetes and CAD. Introduction. (2011) (5)
- Abstract 818: Plasminogen Activator Inhibitor-1 is Reduced by the Once-Daily Human Glucagon-Like Peptide-1 Analog Liraglutide When Used in the Treatment of Type 2 Diabetes (2009) (4)
- A REMOTE LIPID MANAGEMENT PROGRAM IMPROVES APPROPRIATE STATIN USE AND CHOLESTEROL LEVELS ACROSS A WIDE POPULATION OF HIGH CARDIOVASCULAR RISK PATIENTS (2018) (4)
- To fast or not to fast: Lipid measurement and cardiovascular disease risk estimation in rural sub-Saharan Africa (2020) (4)
- Short Communication Macrophages in Human Atheroma Contain PPARg Differentiation-Dependent Peroxisomal Proliferator-Activated Receptor g (PPARg) Expression and Reduction of MMP-9 Activity through PPARg Activation in Mononuclear Phagocytes in Vitro (1998) (3)
- Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics (2022) (3)
- Impact of pre-diabetes on heart transplant outcomes in patients with advanced heart failure. (2014) (3)
- and Migration in Human Vascular Smooth Muscle Cells Peroxisome Proliferator-Activated Receptor Gamma Activators Inhibit Gene Expression (1998) (3)
- Impact of coronary artery calcium testing on patient management. (2021) (3)
- Intersecting vectors of basic science research and clinical medicine: LOX-1? (2010) (3)
- Evaluating the cardiovascular effects of the thiazolidinediones and their place in the management of type 2 diabetes in relation to the metabolic syndrome. (2005) (3)
- Exogenous and endogenous mechanisms of PPAR activation: implications for inflammation and atherosclerosis (2004) (3)
- Shortwave infrared spatial frequency domain imaging for non-invasive measurement of tissue and blood optical properties (2022) (3)
- Mig, and I-TAC in Human Endothelial Cells of the T Cell-Active CXC Chemokines IP-10, -Induced Expression g Activators Inhibit IFN-g Peroxisome Proliferator-Activated Receptor-Jorge (2000) (3)
- Therapeutic Targets Activated Receptors as Transcriptional Nodal Points and − Peroxisome Proliferator (2007) (2)
- Cardiovascular Risk and Statin Eligibility of Young Adults After an MI (2018) (2)
- Hyperhomocysteinemia in acute hepatic porphyria (AHP) and implications for treatment with givosiran (2022) (2)
- BEMPEDOIC ACID 180 MG + EZETIMIBE 10 MG FIXED-DOSE COMBINATION VS EZETIMIBE ALONE OR PLACEBO IN PATIENTS WITH TYPE 2 DIABETES AND HYPERCHOLESTEROLEMIA (2020) (2)
- Correction: Adipocyte arrestin domain-containing 3 protein (Arrdc3) regulates uncoupling protein 1 (Ucp1) expression in white adipose independently of canonical changes in β-adrenergic receptor signaling (2017) (2)
- Pathophysiology of Atherosclerotic Heart Disease (2003) (2)
- (Mis)interpreting studies on the adverse effects of statins (2014) (2)
- Cold-mediated regulation of systemic retinol transport controls adipose tissue browning (2020) (1)
- PPARs and Their Emerging Role in Vascular Biology, Inflammation, and Atherosclerosis (2005) (1)
- Lipoprotein(a), Oxidized Phospholipids, and Coronary Artery Disease Severity and Outcomes. (2023) (1)
- Atherogenesis, coronary heart disease and insulin resistance syndrome in diabetes (2015) (1)
- Population Health Identification and Management of Low Density Lipoprotein Cholesterol via a Remote, Algorithmic, Navigator-Executed Program. (2021) (1)
- PPARg in the endothelium regulates metabolic responses to high-fat diet in mice (2018) (1)
- Endothelial Biomedicine: Peroxisome Proliferator-Activated Receptors and the Endothelium (2007) (1)
- Eff ects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis : a randomised , double-blind , placebo-controlled trial (2015) (1)
- Abstract 15089: Specificity for Inflammatory Pathways and Myocardial Injury Associated With Coronary Microvascular Dysfunction in Rheumatoid Arthritis (2020) (1)
- The endocannabinoid system and the regulation of energy metabolism (2006) (1)
- Atherosclerotic cardiovascular disease risk and elevated lipoprotein(a) among young adults with myocardial infarction: The Partners YOUNG-MI Registry. (2020) (1)
- PPARα and Atherosclerosis (2002) (1)
- LIPID ABNORMALITIES IN YOUNG PATIENTS WITH MYOCARDIAL INFARCTION (2017) (1)
- Obesity and atherosclerotic vascular disease (2006) (1)
- The Pleiotropic Effects of Statins : Fact or Fantasy ? (1)
- PPARs: altering clinical responses in Type 2 diabetes and atherosclerosis. Introduction. (2004) (1)
- BRD2 regulation of sigma-2 receptor expression upon cytosolic cholesterol deprivation (2019) (1)
- PREVALENCE AND TESTING OF LIPOPROTEIN(A) AMONG YOUNG ADULTS WITH MYOCARDIAL INFARCTION: THE PARTNERS YOUNG-MI REGISTRY (2020) (1)
- PPAR and cardiovascular risk (2001) (1)
- Evaluation of Mitral Valve Regurgitation : Implications for Percutaneous Mitral Valve Repair (1)
- Emerging epigenetic maps in atherosclerosis. (2014) (0)
- SCALING SECONDARY PREVENTION: MEDICATION OPTIMIZATION IN PATIENTS WITH ASCVD (2021) (0)
- Abstract 17360: Four Factors Explain Most of the Gender Disparity in Statin Therapy (2014) (0)
- Non-invasive Blood Lipid Monitoring using Shortwave Infrared Spatial Frequency Domain Imaging (SWIR SFDI) (2022) (0)
- A REPORT BY THE CARDIOVASCULAR DIVISION OF BRIGHAM AND WOMEN'S HOSPITAL, BOSTON, MASSACHUSETTS Cardiology Cardiology SCIENTIFIC UPDATE SCIENTIFIC UPDATE (2001) (0)
- Cardiovascular Risk and Statin Eligibility of Young Adults After an MI: Partners (2018) (0)
- WOMEN WHO EXPERIENCE MYOCARDIAL INFARCTION AT A YOUNG AGE HAVE WORSE SURVIVAL COMPARED WITH MEN (2017) (0)
- Oxidized omega-3 fatty acids in fish oil inhibit leukocyte-endothelial interactions through activation of PPARα Short title: Oxidized n-3 fatty acids inhibit inflammation via PPARα (2002) (0)
- Abstract 582: A Novel PPAR{delta}-Hepatic Lipase Transcriptional Pathway (2007) (0)
- interactions through activation of PPARalpha Oxidized omega-3 fatty acids in fish oil inhibit leukocyte-endothelial (2010) (0)
- Abstract 14109: Statin Eligibility Among Young Adults Prior to Myocardial Infarction (2017) (0)
- Myocardial Infarction in the Younger Patient (1999) (0)
- 2218-PUB: Initiation of SGLT2 Inhibitors in Hospitalized Patients with CVD (2020) (0)
- Abstract 1556: Retinaldehyde Inhibits Adipogenesis Through RXR and PPAR-gamma Repression (2006) (0)
- as a Potential Mediator in Vascular Disease γ Type-1 Expression : PPAR Activation in Human Endothelial Cells Increases Plasminogen Activator Inhibitor γ PPAR (1999) (0)
- FOCUS ON RETEPLASE : A NEWLY APPROVED THIRD-GENERATION THROMBOLYTIC AGENT FOR THE TREATMENT OF ACUTE MYOCARDIAL INFARCTION (1997) (0)
- A miRNA/CXCR4 signaling axis impairs monopoiesis and angiogenesis in diabetic critical limb ischemia (2023) (0)
- Abstract 12649: Remote, Integrated Algorithm-based CV Risk Management Program Improves Hypertension and LDL Control (2019) (0)
- Abstract: 124 PATHOPHYSIOLOGY OF MET SYN AND RELATED CARDIOMETABOLIC RISK: WHAT'S NEW? (2009) (0)
- Scattering and hemodynamic changes after a high-fat meal measured with SFDI (Conference Presentation) (2023) (0)
- Relationship Between Risk of Atherosclerotic Cardiovascular Disease, Inflammation, and Coronary Microvascular Dysfunction in Rheumatoid Arthritis (2022) (0)
- Expression in Human Endothelial Cells Activators Inhibit Cytokine-Induced Vascular Cell Adhesion Molecule-1 α PPAR (1999) (0)
- Managing Dyslipidemia and Global Risk in Patients with Type 2 Diabetes and Insulin Resistance Managing Dyslipidemia and Global Risk in Patients with Type 2 Diabetes and Insulin Resistance (2005) (0)
- Abstract: 511 THE RXR-PPAR COMPLEX IN THE REGULATION OF ENERGY BALANCE (2009) (0)
- Association of monocyte TNF α expression and serum inflammatory biomarkers with walking impairment in PAD (2014) (0)
- Effect of a Peroxisome Proliferator–Activated Receptor- (cid:1) Agonist on Myocardial Blood Flow in Type 2 Diabetes (2005) (0)
- The Veterans Administration-HDL Intervention Trial (VA-HIT) (1998) (0)
- Impaired angiogenesis in diabetic critical limb ischemia is mediated by a miR-130b-INHBA signaling axis. (2023) (0)
- The Peroxisome Proliferator-Activated Receptor- (cid:1) Agonist Pioglitazone Represses Inflammation in a Peroxisome Proliferator-Activated Receptor- (cid:2) – Dependent Manner In Vitro and In Vivo in Mice (2008) (0)
- Introduction (2004) (0)
- patients The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic (2011) (0)
- Abstract 17798: Statin Persistence After Reported Adverse Reactions and Patient Outcomes (2015) (0)
- CARDIOVASCULAR BIOMARKERS OF LIPIDS AND SUBCLINICAL MYOCARDIAL INJURY DIVERGE DURING RHEUMATOID ARTHRITIS FLARE (2020) (0)
- Abstract 3436: Endothelial PPAR{gamma} Regulates Lipid Metabolism And Adiposity After High Fat Feeding (2008) (0)
- Abstract 16195: Socioeconomic Disadvantage is Associated With Higher Long-Term Cardiovascular Mortality Following Myocardial Infarction: The YOUNG-MI Registry (2020) (0)
- Jorge Plutzky Emerging Epigenetic Maps in Atherosclerosis (0)
- STATIN INTOLERANCE: A REMOTE, NAVIGATOR-LED STRATEGY TO COMBAT A COMMON CHALLENGE (2021) (0)
- THE RELATIONSHIP BETWEEN ASCVD RISK, INFLAMMATION, AND CORONARY MICROVASCULAR DYSFUNCTION IN RHEUMATOID ARTHRITIS (2022) (0)
- Abstract 5471: Peroxisome Proliferator-Activated Receptor-{gamma} Activation Reduces Inflammation in Atherosclerosis as Assessed by Serial In Vivo Fluorescence Molecular Imaging (2008) (0)
- PPARs in Atherosclerosis (2008) (0)
- Abstract 181: BET Bromodomain Inhibition Suppresses Endothelial Inflammation and Atherosclerosis (2013) (0)
- Abstract 036: LDL-Cholesterol Lowering Among Young Adults Who Experience a First Myocardial Infarction (2017) (0)
- The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes (Acute Coronary Syndromes Through Renal Disease) and Future Directions (2006) (0)
- Clinic-ready shortwave infrared spatial frequency domain imaging (SWIR SFDI) system for non-invasive monitoring of postprandial blood lipids (2022) (0)
- Epigenetic Therapeutics for Cardiovascular Disease: Writing, Erasing, Reading, and Maybe Forgetting. (2020) (0)
- Cardiovascular Disease Prevention (2012) (0)
- Diabetes as a vascular disease. Dyslipidemia as a target. (2003) (0)
- Hyperlipidemia After Allogeneic Hematopoietic Stem Cell Transplantation. (2010) (0)
- Abstract 12910: Use of Optimal Medical Therapy in Patients With Cardiovascular Disease Undergoing Cardiac Rehabilitation (2020) (0)
- The Aging Aorta: Are We Only as Old as Our Endothelium? (2022) (0)
- Edinburgh Research Explorer Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design (2020) (0)
- PPARs in Diabetes and Cardiovascular Disease (2006) (0)
- Perivascular Fibrosis Is Mediated by a KLF10-IL-9 Signaling Axis in CD4+ T Cells (2022) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Jorge Plutzky?
Jorge Plutzky is affiliated with the following schools: